Literature DB >> 32390141

LncRNA TUG1 facilitates proliferation, invasion and stemness of ovarian cancer cell via miR-186-5p/ZEB1 axis.

Fu-Liang Zhan1, Chun-Fang Chen2, Mei-Zhen Yao1.   

Abstract

LncRNA TUG1 has been rarely studied in ovarian cancer (OC), our objective was to explore the role of TUG1 in the regulation of malignant phenotypes of OC. Vectors of sh-TUG1, miR-186-5p and pcDNA-ZEB1 were, respectively, constructed and used to infect OC cells. MTT and transwell assays were applied for representing cell proliferation and invasion, respectively. Sphere formation experiment was used to detect the stemness of OC cells. Western blotting and qRT-PCR were employed for detecting the expression of multiple biomarkers on protein and RNA levels, respectively. The luciferase assay was performed to reveal the interactions between miR-186-5p and TUG1 or ZEB1. The silencing of TUG1 and upregulation of miR-186-5p both suppressed the cell proliferation, invasion and cancer stem cell (CSC) properties. Additionally, luciferase assay verified that miR-186-5p directly binds TUG1 and ZEB1. Moreover, overexpression of ZEB1 rescued the impact on the proliferation, invasion and stemness of TUG1 silencing in OC. TUG1 sponges miR-186-5p to release ZEB1 and promotes the proliferation, invasion and stemness of OC cells, suggesting that TUG1 could be a potential therapeutic target for OC therapy. SIGNIFICANCE OF THE STUDY: LncRNA TUG1 could promote proliferation, invasion and stemness of ovarian cancer cells. Our study first discovered that TUG1 play a tumourigenic role in ovarian cancer by regulating stemness of cancer cells. Mechanism research exhibited the regulation role of TUG1 in ovarian cancer cells was miR-186-5p/ZEB1 axis depended. These results provided a new perspective to understand the pathogenesis and development of ovarian cancer; it will offer new evidence for better diagnosis and treatment therapy of ovarian cancer.
© 2020 The Authors. Cell Biochemistry and Function published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ZEB1; cancer stem cell; lncRNA TUG1; miR-186-5p; ovarian cancer

Mesh:

Substances:

Year:  2020        PMID: 32390141     DOI: 10.1002/cbf.3544

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  6 in total

1.  Long non-coding RNA TUG1/microRNA-187-3p/TESC axis modulates progression of pituitary adenoma via regulating the NF-κB signaling pathway.

Authors:  Rui Zhang; Fan Yang; Haitao Fan; Haocong Wang; Qinghao Wang; Jianxin Yang; Tao Song
Journal:  Cell Death Dis       Date:  2021-05-21       Impact factor: 8.469

2.  LncRNA TUG1 Promotes Apoptosis, Invasion, and Angiogenesis of Retinal Endothelial Cells in Retinopathy of Prematurity via MiR-145-5p.

Authors:  Yuexia Wang; Yue Wang; Xue Wang; Yuan Ma; Zhaojin Li; Yu Di
Journal:  Front Med (Lausanne)       Date:  2022-04-04

Review 3.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

4.  High Expression of EIF4G2 Mediated by the TUG1/Hsa-miR-26a-5p Axis Is Associated with Poor Prognosis and Immune Infiltration of Gastric Cancer.

Authors:  Liu Fu; Zhe Wang; Fengxiang Jiang; Guohua Wei; Longe Sun; Chuanyong Guo; Jianye Wu; Jianhuan Zhu
Journal:  J Oncol       Date:  2022-09-16       Impact factor: 4.501

5.  Hsa_circRNA_0001971 contributes to oral squamous cell carcinoma progression via miR-186-5p/Fibronectin type III domain containing 3B axis.

Authors:  Jiehua Zhang; Youjian Peng; Shengjun Jiang; Jun Li
Journal:  J Clin Lab Anal       Date:  2022-01-21       Impact factor: 3.124

6.  Development and Validation of a Novel Stemness-Index-Related Long Noncoding RNA Signature for Breast Cancer Based on Weighted Gene Co-Expression Network Analysis.

Authors:  Da Qian; Cheng Qian; Buyun Ye; Ming Xu; Danping Wu; Jialu Li; Dong Li; Bin Yu; Yijing Tao
Journal:  Front Genet       Date:  2022-02-22       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.